Abstract

Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/00 - Drugs for disorders of the senses

Abstract

Disclosed herein are methods of treating chemosensory dysfunction in a subject, comprising administering to the subject a device such as a stent comprising a phosphodiesterase inhibitor. Also disclosed herein are devices comprising phosphodiesterase inhibitors, and kits comprising devices comprising phosphodiesterase inhibitors.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/00 - Drugs for disorders of the senses

Abstract

Disclosed herein are methods of treating a chemosensory dysfunction in a subject, comprising intranasally administering to the subject a phosphodiesterase inhibitor or a salt thereof by a nasal spray device. Also disclosed herein are devices and kits for administering phosphodiesterase inhibitors or salts thereof to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction from a viral infection or another underlying cause of chemosensory dysfunction.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4515 - Non-condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 27/00 - Drugs for disorders of the senses

Abstract

Disclosed herein are methods of treating an allergic rhinitis, a nasal polyp, and/or a sinusitis in a subject, comprising intranasally administering to the subject a corticosteroid, an ester thereof, or a salt thereof by a nasal spray device. Also disclosed herein are devices and kits for administering corticosteroids, esters thereof, or salts thereof to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat the diseases disclosed herein.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 11/02 - Nasal agents, e.g. decongestants

Abstract

Disclosed herein are methods of treating Parkinson's disease in a subject, comprising intranasally administering to the subject phosphodiesterase inhibitors and treatments for Parkinson's disease by a nasal spray device. Also disclosed herein are devices and kits for administering the compositions described herein to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction resulting from Parkinson's disease. Also described herein are treatments of other neurological diseases by a nasal spray device.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are methods of treating chemosensory dysfunction in a subject, comprising administering to the subject a gel comprising a phosphodiesterase inhibitor. Also disclosed herein are methods of treating chemosensory dysfunction by administering a phosphodiesterase inhibitor to a subject in need thereof. Also disclosed herein are kits comprising gels.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 27/00 - Drugs for disorders of the senses

Abstract

Disclosed herein are methods of treating a chemosensory dysfunction in a subject, comprising intranasally administering to the subject a phosphodiesterase inhibitor, a salt thereof, an anticonvulsant, a salt thereof, or any combination thereof by a nasal spray device. Also disclosed herein are devices and kits for administering phosphodiesterase inhibitors and/or anticonvulsants to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction from a viral infection or another underlying cause of chemosensory dysfunction.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 47/38 - CelluloseDerivatives thereof
• A61M 15/08 - Inhaling devices inserted into the nose
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

Disclosed herein are methods of treating a memory loss in a subject, comprising intranasally administering to the subject a phosphodiesterase inhibitor or a salt thereof by a nasal spray device. Also disclosed herein are devices and kits for administering phosphodiesterase inhibitors or salts thereof to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat a memory loss and/or a cognitive decline in a subject.

IPC Classes  ?

• A61M 15/08 - Inhaling devices inserted into the nose
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

IPC Classes  ?

• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/00 - Drugs for disorders of the senses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 15/08 - Inhaling devices inserted into the nose

Abstract

Disclosed herein are methods of treating a chemosensory dysfunction in a subject, comprising intranasally administering to the subject a phosphodiesterase inhibitor or a salt thereof by a nasal spray device. Also disclosed herein are devices and kits for administering phosphodiesterase inhibitors or salts thereof to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction from a viral infection or another underlying cause of chemosensory dysfunction.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Disclosed herein are methods of treating Parkinson's disease in a subject, comprising intranasally administering to the subject phosphodiesterase inhibitors and treatments for Parkinson's disease by a nasal spray device. Also disclosed herein are devices and kits for administering the compositions described herein to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat chemosensory dysfunction resulting from Parkinson's disease. Also described herein are treatments of other neurological diseases by a nasal spray device.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/52 - Purines, e.g. adenine
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Disclosed herein are methods of treating an allergic rhinitis, a nasal polyp, and/or a sinusitis in a subject, comprising intranasally administering to the subject a corticosteroid, an ester thereof, or a salt thereof by a nasal spray device. Also disclosed herein are devices and kits for administering corticosteroids, esters thereof, or salts thereof to a subject in need thereof. The nasal spray devices herein deliver a dosage unit that can be used to treat the diseases disclosed herein.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 11/06 - Antiasthmatics
• A61P 11/08 - Bronchodilators
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/08 - Antiallergic agents
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Disclosed herein are methods of treating chemosensory dysfunction in a subject, comprising administering to the subject a device such as a stent comprising a phosphodiesterase inhibitor. Also disclosed herein are devices comprising phosphodiesterase inhibitors, and kits comprising devices comprising phosphodiesterase inhibitors.

IPC Classes  ?

• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums
• A61F 2/02 - Prostheses implantable into the body
• A61L 31/08 - Materials for coatings
• A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure

Abstract

Disclosed herein are methods of treating chemosensory dysfunction in a subject, comprising administering to the subject a gel comprising a phosphodiesterase inhibitor. Also disclosed herein are methods of treating chemosensory dysfunction by administering a phosphodiesterase inhibitor to a subject in need thereof. Also disclosed herein are kits comprising gels.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 27/00 - Drugs for disorders of the senses
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/14 - Antivirals for RNA viruses
• A61P 27/00 - Drugs for disorders of the senses
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

IPC Classes  ?

• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/52 - Purines, e.g. adenine
• A61P 27/00 - Drugs for disorders of the senses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Abstract

Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.

IPC Classes  ?

• A61P 31/12 - Antivirals
• A61P 37/02 - Immunomodulators
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/02 - Nasal agents, e.g. decongestants

Goods & Services

nasal spray preparations; pharmaceutical preparations to aid in the restoration of taste and smell; pharmaceutical preparations; medical diagnostic reagents. Medical devices; receptacles for applying medicines; nasal aspirators; nasal sprayers.

Goods & Services

(1) Nasal spray preparations; pharmaceutical preparations to aid in the restoration of taste and smell

Abstract

Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61P 27/00 - Drugs for disorders of the senses

Abstract

Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

IPC Classes  ?

• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/52 - Purines, e.g. adenine
• A61P 27/00 - Drugs for disorders of the senses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 38/26 - Glucagons
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Goods & Services

nasal spray preparations; pharmaceutical preparations to aid in the restoration of taste and smell

Abstract

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Abstract

Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings

Abstract

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods and compositions are provided for detection of biological substances in nasal specimen.

IPC Classes  ?

• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 35/24 - MucusMucous glandsBursaSynovial fluidArthral fluidExcretaSpinal fluid
• C12P 19/30 - Nucleotides
• G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Methods and compositions are provided for detection of biological substances in nasal specimen.

IPC Classes  ?

• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A cable-raceway providing electromagnetic shielding has rectangular channels defined by longitudinal-folds of a tape which comprises mesh having a warp of bare wires running lengthwise and a weft of a single, bare-wire. Metal brackets support it with the base of each bracket extending transversely under the raceway. The channels nest between arms upstanding from the base, and a plastic insert fits over the tape to enhance electrical contact between the mesh and bracket for electrical ground-bonding of the raceway. The insert provides teeth down the walls of each channel for engagement by cable-retainers to push them down into the channels for retaining underlying cables. Further support in the channels is provided by plastic straps that extend under the raceway and to which the channels are secured using inserts and cable-retainers corresponding to the inserts and retainers. One face of the mesh is covered by an electrically-insulating sheet.

IPC Classes  ?

• H02G 3/04 - Protective tubing or conduits, e.g. cable ladders or cable troughs
• H02G 3/08 - Distribution boxesConnection or junction boxes
• H02B 1/40 - Wall-mounted casingsParts thereof or accessories therefor
• H02G 3/22 - Installations of cables or lines through walls, floors or ceilings, e.g. into buildings

Abstract

Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/47 - QuinolinesIsoquinolines

Abstract

Methods and compositions are provided for detection of biological substances in nasal specimen.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods

Abstract

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• A61P 11/02 - Nasal agents, e.g. decongestants

Abstract

Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.

IPC Classes  ?

• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/47 - QuinolinesIsoquinolines

Abstract

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• A61K 38/28 - Insulins